Global Burden of Metabolic Dysfunction-associated Steatotic Liver Disease Attributable to High Fasting Plasma Glucose in 204 Countries and Territories from 1990 to 2021

Overview

Journal Sci Rep

Specialty Science

Date 2024 Sep 27

PMID 39333707

Authors

Ziming Yang

Aolin Li

Yuling Jiang

Xiagela Maidaiti

Yinge Wu

Yinzi Jin

Affiliations

Soon will be listed here.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) brings heavy clinical and economic burdens to patients worldwide. High fasting plasma glucose (HFPG) was proven to be an important modifiable risk factor. However, the global burden distribution of HFPG-attributable MASLD has not been fully studied. This study aimed to describe the epidemiological distribution and trends of the burden of HFPG-attributable MASLD worldwide. The data source was the 2021 Global Burden of Disease Study. Descriptive statistics were mainly conducted using disability-adjusted life years (DALYs) and deaths of HFPG-attributable MASLD from 1990 to 2021, as well as their age-standardized rates (ASRs) and population-attributable fractions. Subgroup analyses were conducted by region, age group, and sex. We found that 213.48 thousand DALYs and 10.02 thousand deaths in MASLD were attributable to HFPG worldwide in 2021, with an increase of 2.96 and 3.32 times compared with 1990, respectively. Over the past 32 years, age-standardized DALY rates (ASDRs) have fluctuated upward, reaching 2.45 per 100,000 people in 2021, with an increase of 81.21%. The ASDRs continued to rise in low, low-middle, and high social demographic index (SDI) regions, fluctuated upward at high levels in middle SDI regions, and were relatively low in high-middle SDI regions. People aged 50-69 accounted for the largest proportion of DALYs, while people over 70 had the largest increase of 3.73 times. Men had higher ASDRs, and the sex difference has been gradually expanding over the past 32 years, peaking at the age of 45-49. In conclusion, the burden of HFPG-attributable MASLD has continued to increase globally, with differences in geographical area, age, and sex distribution. HFPG, as a modifiable risk factor, should be given more importance. The implementation of targeted health intervention strategies is recommended for each country based on trends in the burden of HFPG-attributable MASLD.

Citing Articles

IFN-γ-mediated inhibition of JAK/STAT signaling via nano-scutellarin treatment is an efficient strategy for ameliorating liver fibrosis.

Wang T, Liu B, Huang J, Zhao Q, Shen H, Bi T J Transl Med. 2025; 23(1):195.

PMID: 39962553 PMC: 11834254. DOI: 10.1186/s12967-025-06155-5.

Spatially resolved rewiring of mitochondria-lipid droplet interactions in hepatic lipid homeostasis.

Kang S, Brown L, Miller C, Barrows K, Golino J, Cultraro C bioRxiv. 2025; .

PMID: 39803529 PMC: 11722523. DOI: 10.1101/2024.12.10.627730.

References

Rinella M, Lazarus J, Ratziu V, Francque S, Sanyal A, Kanwal F . A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023; 79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.003. View

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

Chen H, Zhan Y, Zhang J, Cheng S, Zhou Y, Chen L . The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. JMIR Public Health Surveill. 2022; 8(12):e34809. PMC: 9793331. DOI: 10.2196/34809. View

Lazarus J, Mark H, Anstee Q, Arab J, Batterham R, Castera L . Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2021; 19(1):60-78. DOI: 10.1038/s41575-021-00523-4. View

Terrault N, Pageaux G . A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!. J Hepatol. 2018; 69(4):767-768. DOI: 10.1016/j.jhep.2018.07.020. View

Phisalprapa P, Prasitwarachot R, Kositamongkol C, Hengswat P, Srivanichakorn W, Washirasaksiri C . Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. BMC Gastroenterol. 2021; 21(1):135. PMC: 7992785. DOI: 10.1186/s12876-021-01720-w. View

Friedman S, Neuschwander-Tetri B, Rinella M, Sanyal A . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24(7):908-922. PMC: 6553468. DOI: 10.1038/s41591-018-0104-9. View

Targher G, Corey K, Byrne C, Roden M . The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18(9):599-612. DOI: 10.1038/s41575-021-00448-y. View

10.

Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S . Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42(1):44-52. DOI: 10.1002/hep.20734. View

11.

Golabi P, Paik J, Kumar A, Al Shabeeb R, Eberly K, Cusi K . Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States. Metabolism. 2023; 146:155642. DOI: 10.1016/j.metabol.2023.155642. View

12.

Tanase D, Gosav E, Costea C, Ciocoiu M, Lacatusu C, Maranduca M . The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020; 2020:3920196. PMC: 7424491. DOI: 10.1155/2020/3920196. View

13.

Saponaro C, Gaggini M, Gastaldelli A . Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015; 15(6):607. DOI: 10.1007/s11892-015-0607-4. View

14.

Liang R, Feng X, Shi D, Yang M, Yu L, Liu W . The global burden of disease attributable to high fasting plasma glucose in 204 countries and territories, 1990-2019: An updated analysis for the Global Burden of Disease Study 2019. Diabetes Metab Res Rev. 2022; 38(8):e3572. DOI: 10.1002/dmrr.3572. View

15.

Rooney M, Fang M, Ogurtsova K, Ozkan B, Echouffo-Tcheugui J, Boyko E . Global Prevalence of Prediabetes. Diabetes Care. 2023; 46(7):1388-1394. PMC: 10442190. DOI: 10.2337/dc22-2376. View

16.

Golabi P, Owrangi S, Younossi Z . Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies. Aliment Pharmacol Ther. 2024; 59 Suppl 1:S1-S9. DOI: 10.1111/apt.17833. View

17.

Bluher M . Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019; 15(5):288-298. DOI: 10.1038/s41574-019-0176-8. View

18.

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan B . IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021; 183:109119. PMC: 11057359. DOI: 10.1016/j.diabres.2021.109119. View

19.

Ye L, Xu J, Zhang T, Lin X, Pan X, Zeng W . Global burden of noncommunicable diseases attributable to high fasting plasma glucose. J Diabetes. 2020; 12(11):807-818. DOI: 10.1111/1753-0407.13072. View

20.

Tsugane S . Why has Japan become the world's most long-lived country: insights from a food and nutrition perspective. Eur J Clin Nutr. 2020; 75(6):921-928. PMC: 8189904. DOI: 10.1038/s41430-020-0677-5. View